t(12;15)(p13;q25) ETV6/NTRK3 in solid tumors

Abstract

Abstract

Review on t(12;15)(p13;q25) in solid tumors, with data on clinics, and the genes involved.

Identity

ICD-Topo	C180,C182-C189,C199 LARGE INTESTINE, (EXCL. APPENDIX)
ICD-Morpho	8825/1
ICD-Morpho	8814/3
ICD-Morpho	8502/3
ICD-Morpho	8960/1
ICD-Morpho	8260/3
ICD-Morpho	9425/3
ICD-Morpho	9401/3
ICD-Morpho	8770/1
ICD-Morpho	8720/3
ICD-Morpho	8140/3
Atlas_Id	5267
Phylum	Digestive organs: Colon-Rectum::
WHO/OMS Classification	Digestive organs

Clinics and Pathology

Note

A t(12;15)(p13;q25) ETV6/NTRK3 has been found: 1) in congenital/infantile fibrosarcoma and cellular mesoblastic nephroma (which may be a renal form of infantile fibrosarcoma), 2) in secretory breast (ductal) carcinoma and in it's analogue in the salivary glands, 3) in acute leukemias (both myeloid and lymphoid), 4) in papillary thyroid carcinoma, often radiation-associated, 5) in inflammatory myofibroblastic tumor, and, in few cases, in other tumors. Equivalents of the ETV6/NTRK3 fusion was also found in rare instances in the above mentioned tumors: EML4 /NTRK3, MYH9 /NTRK3, MYO5A /NTRK3, LMNA / NTRK1, and ETV6/?

Disease	Congenital/infantile fibrosarcoma (WHO/OMS 8814/3) (CIF)
Note	Congenital/infantile fibrosarcoma is a low-grade malignant spindle cell tumor of the soft tissues that usually presents before the age of 2 years (diagnosed at birth in 40%, before 6 months in 60% of cases, more common in boys than in girls), occurring 1) most often in the extremities and with a good prognosis, at times 2) in the axial skeleton with a somewhat worse prognosis. Local recurrence is common (10 to 30 % of cases) but metastases are rare. Overall 5-year survival is at least 90% (Farmakis et al., 2014). CIF accounts for 10% of soft tissue tumors in infants.
Cytogenetics	A t(12;15)(p13;q25) ETV6/NTRK3 was found in most cases, but is not found in either infantile fibromatosis, a close but benign entity, or in fibrosarcoma of the adulthood. The t(12;15) ETV6/NTRK3 is most often accompanied with trisomy or tetrasomy 11 (Knezevich et al., 1998; Rubin et al., 1998; Bourgeois et al., 2000; Punnett et al., 2000; Argani et al., 2001; Dubus et al., 2001; Sheng et al., 2001; Miura et al., 2002; McCahon et al., 2003; Ramphal et al., 2003; Morerio et al., 2004; Nonaka and Sun, 2004; Himori et al., 2005; Rizkalla et al., 2011). The reciprocal NTRK3/ETV6 fusion product may also be found, with NTRK3 exon 14 fused to ETV6 exon 6 (Dubus et al., 2001). A t(2;15)(p21;q24) EML4/NTRK3 has also been found in two cases of CIF. One was a 9-mo-old male patient with recurrent congenital fibrosarcoma and a history of left upper extremity hemimelia without other congenital anomalies. Exon 2 of EML4 was fused to exon 14 of NTRK3 (Tannenbaum-Dvir et al., 2015; Church et al., 2018). A congenital infantile fibrosarcoma was found to harbor a LMNA/NTRK1 gene fusion (Wong et al., 2015).

Disease	Congenital Mesoblastic Nephroma (WHO/OMS 8960/1) (CMN)
Note	Congenital mesoblastic nephroma is the most common kidney tumor found in infants younger than 6 months and and accounts for 3-5% of all paediatric renal neoplasm. The 5-year event-free survival rate is 95%. Histopathologically, it consist of spindled cells. There are three histologic subtypes: classic, mixed, and cellular. The cellular subtype is identical to infantile fibrosarcoma and is the form with a t(12;15) ETV6/NTRK3 and trisomy 11 (PDQ Pediatric Treatment Editorial Board, 2019). Cellular mesoblastic nephroma tends to present later in infanc than the classic formy, and can exhibit aggressive behavior including metastases (Bayindir et al., 2009). It has been suggested that the cellular subtype represents in fact congenital infantile fibrosarcoma occurring in the kidney (Bayindir et al., 2009; El Demellawy et al., 2016). A t(12;15) ETV6/NTRK3, most often accompanied with trisomy or tetrasomy 11, or a fusion ETV6/NTRK3 has been found in more than 40 cases; some cases were mixed forms; none was classical form (Rubin et al., 1998; Knezevich et al., 1998; Argani et al., 2000; Ramachandran et al., 2001; Watanabe et al., 2002; Henno et al., 2003; Anderson et al., 2006; Bayindir et al., 2009).
Cytogenetics	Although the t(12;15)(p13;q25) ETV6/NTRK3 was found in most cases , a t(2;15)(p21;q24) EML4/NTRK3 has also been found in one case of CMN (Church et al., 2018).

Disease	Breast Ductal carcinoma - Secretory breast carcinoma subtype (WHO/OMS 8502/3) (SBC)
Note	Secretory breast carcinoma is a rare (less than 0.15% of all breast cancers) subtype of breast ductal carcinoma (but the most common breast cancer in the pediatric population), with a distinct morphology: eosinophilic secretion and positive periodic acid-Schiff (PAS) secretions are seen, immune-positivity for S100 and mammaglobin, most often triple negativity (ESR1/2-, PGR-, ERBB2-)) and an excellent prognosis in children and adolescents. It occurs in both children and adults with a wide age range from 3 to 83 years. Most reported cases are in young women, with a median age of 25 years. There are only 120 cases published in literature, including 32 in male patients. Breast secretory carcinoma is a slow-growing, low-grade subtype of infiltrating ductal carcinoma. The disease seems slightly more aggressive in adults (Vasudev and Onuma 2011; Ghilli et al., 2018).
Cytogenetics	A t(12;15)(p13;q25) ETV6/NTRK3 was found in most cases (Tognon et al., 2002; Diallo et al., 2003; Stransky et al 2014).
Genes	ETV6/NTRK3 chimeric product can transform normal mouse mammary epithelial cells. Fusion was between ETV6 nucleotide 1033 and NTRK3 nucleotide 1601 as previously shown for sarcoma-associated fusions (Knezevich et al., 1998). This differs from the ETV6/NTRK3 gene fusion reported in a case of acute myeloid leukemia, in which ETV6 exon 5 was not present in the fusion (Eguchi et al., 1999). The rare secretory breast carcinomas with metastases, more aggressive tumors, showed amplification of the 16p13.3 locus, a TERT promotor mutation and loss of 9p21.3 locus (Hoda et al., 2019).

Disease	Mammary analogue secretory carcinoma of salivary glands (MASC)
Note	A t(12;15)(p13;q25) ETV6/NTRK3 was found in salivary gland tumors (mostly from the parotid gland) with histo-morphologic and immune-histochemical features reminiscent of secretory carcinoma of the breast, with eosinophilic secretion, positivity for PAS, S-100 protein and mammaglobin (Skálová et al., 2010; Chiosea et al., 2012; Connor et al., 2012; Skálová et al., 2014; Pinto et al., 2014). More than 250 cases have been described (review in Skálová et al., 2017). Mean age was 47 years (14-78 years), there is a slight male predominance. MASC mimick other salivary tumors, most often adenocarcinoma, not otherwise specified and acinic cell carcinomas. MASC usually behaves indolently, but like other low-grade salivary gland carcinomas, there is some loco-regional recurrence and distant metastases (Skálová et al., 2017).
Cytogenetics	A t(12;15)(p13;q25) ETV6/NTRK3 was found in most cases. A few cases where ETV6 was fused with an unknown partner different from NTRK3 were described; these may behave more aggressively (Ito et al., 2015; Skálová et al., 2016).

Disease

Thyroid: Papillary thyroid carcinoma (WHO/OMS 8260/3) (PTC)

Note

In an analysis of 62 radiation-associated papillary thyroid carcinomas post-Chernobyl (iodine-131 exposure), 9 (14.5%) of PTCs harbored ETV6/NTRK3 rearrangement; ETV6/NTRK3 fusion was the second most common rearrangement type after "RET/PTC". Further screening of 151 sporadic PTCs revealed three positive cases, resulting in a prevalence of 2%. The majority of post-radiation-associated PTCs with ETV6/NTRK3 rearrangement were classified as the follicular variant of PTC (Leeman-Neill et al 2014). In a study of 496 papillary thyroid carcinoma without radiation exposure, and classified as low risk, 5 cases (three "classical", one "follicular") presented with an ETV6/NTRK3 rearrangement. Ages and sex: were: 41/F, 36/F, 23/F, 17/F) (The Cancer Genome 2014). Another genome sequencing study from "The Cancer Genome Atlas" (TCGA) found 6 such cases (Stransky et al 2014).

Disease

Inflammatory myofibroblastic tumor/myofibroblastic sarcoma (WHO/OMS 8825/1) (IMT)

Note

Inflammatory myofibroblastic tumor is a rare visceral and soft tissue tumor (commonly seen in the lung), consisting of myofibroblastic spindle cells with inflammatory cells. Local recurrences are seen in about 25% of patient, but metastases are rare. It affects primarily children and young adults, with a slight male predominance. Favorable outcome is documented in most cases. An ETV6/NTRK3 fusion was found in at least 6 cases of .inflammatory myofibroblastic tumor: in a 17-year-old girl and in 2 other cases in a subset of ALK-negative inflammatory myofibroblastic tumors, in a 7-year old child and in a 23-year-old adult patient, and in a 44-year-old female patient (Alassiri et al 2016; Yamamoto et al 2016; Takahashi et al 2018).

Disease	Skin melanocytic tumors (WHO/OMS 8770/1 and 8720/3) and other skin carcinomas
Note	A t(12;15)(p13;q25) ETV6/NTRK3 was found in 4 cases of atypical Spitz tumors (Yeh et al., 2016), a group of cutaneous melanocytic tumors (Murali et al., 2012 http://atlasgeneticsoncology.org/Tumors/SpitzTumorID6241.html). Ages and sex were: 2/F, 6/F, 7/M, and 10/F (Yeh et al., 2016). An ETV6/NTRK3 fusion was also detected in a skin melanoma in massive data sets from genome sequencing studies from the TCGA (Stransky et al 2014). Asecretory carcinoma of the skin mimicking secretory carcinoma of the breast and the and secretory carcinoma salivary gland was found to harbor an ETV6/NTRK3 fusion gene (Huang et al., 2016)
Cytogenetics	Other cases presented with the following translocations/genes fusions: MYH9/NTRK3 and MYO5A/NTRK3. In all those cases, NTRK3 fusions constitutively activated the RAS/RAF/MAPK, PI3K/AKT/MTOR and PLCG pathways in melanocytes (Yeh et al., 2016).

Disease	Brain tumors (WHO/OMS 9425/3 9401/3)
Note	In a series of 149 pediatric low-grade gliomas, an ETV6/NTRK3 fusion was found in a 13-year-old girl with a pilomyxoid astrocytoma (Zhang et al 2013). An ETV6/NTRK3 fusion was also found in a high grade astrocytoma (massive data from genome sequencing) (Wu et al 2014).
Cytogenetics	The reciprocal NTRK3/ETV6 fusion product was also found (Zhang et al 2013).

Disease	Colon adenocarcinoma (WHO/OMS 8140/3)
Note	At least 4 cases of colorectal carcinoma were found to have an ETV6/NTRK3 fusion, in massive data from genome sequencing studies from the TCGA (Seshagiri et al 2012; Stransky et al 2014; Hu et al 2018).

Disease	Sinonasal adenocarcinoma
Note	Two cases of low grade sinonasal adenocarcinoma were found to have the t(12;15)(p13;q25) ETV6/NTRK3 (Andreasen et al 2017).
Cytogenetics	Another case presented with ETV6 fused to an unknown partner (Andreasen et al 2017).

Genes involved and Proteins

Gene Name	ETV6 (ets variant 6)
Location	12p13.2
Protein	ETV6 is a strong transcriptional repressor. ETV6 is a 452 amino acid member of the ETS family (signal-dependent transcriptional regulators, mediating cell proliferation, differentiation and tumorigenesis). The ETV6 protein contains two major domains, the HLH (helix-loop-helix) and ETS domains. The N-term HLH domain, also referred to as the pointed or sterile alpha motif domain, is responsible for hetero- and homo-dimerization. The C-term ETS domain is responsible for sequence specific DNA-binding and protein-protein interaction. A central domain, called internal domain, is involved in the recruitment of a repression complex including NCOR1, NCOR2, and SIN3A (Braekeleer et al., 2014 http://atlasgeneticsoncology.org//Genes/ETV6ID38.html ).

Gene Name	NTRK3 (neurotrophic tyrosine kinase, receptor, type 3)
Location	15q25.3
Protein	NTRK3 is a transmembrane receptor tyrosine kinase which triggers PI3K/AKT, RAS/RAF/MAPK, and PLCG pathways. NTRK3 is a 839 amino acid protein with a N-term extra-cellular ligand binding domain, a transmembrane domain, and a C-term intracellular tyrosine kinase domain. Ligand for NTRK3 is NTF3 (neurotrophin 3) (Knezevich 2004 http://atlasgeneticsoncology.org/Genes/NTRK3ID433.html).

Result of the chromosomal anomaly

Hybrid Gene
Description	In solid tumors, ETV6 exon 5 - NTRK3 exon 15 fusion is the most frequent: The fusion was exon 4 - exon 14 in most papillary thyroid carcinoma ceases, but one exon 5 - exon 14 fusion case was also found (Leeman-Neill et al., 2014) The fusion was exon 5 - exon 15 in: secretory ductal breast carcinoma (Tognon et al., 2002), congenital mesoblastic nephroma (Knezevich et al., 1998; Rubin et al., 1998; Argani et al., 2000; Ramachandran et al., 2001; Watanabe et al., 2002; Henno et al., 2003; Anderson et al., 2006; Bayindir et al., 2009), secretory carcinoma of salivary glands (mammary analogue) (Skálová et al., 2010; Skálová et al., 2014), atypical Spitz tumors (Yeh et al., 2016), and also in a case of colon adenocarcinoma (Seshagiri et al., 2012). The classical exon 5 - exon 15 fusion is also found in congenital/infantile fibrosarcoma (Knezevich et al., 1998; Rubin et al., 1998; Bourgeois et al., 2000; Punnett et al., 2000; Argani et al., 2001; Dubus et al., 2001; Sheng et al., 2001; Miura et al., 2002; McCahon et al., 2003; Ramphal et al., 2003; Nonaka and Sun, 2004; Himori et al., 2005), but, also, a fusion NTRK3 exon 14 - ETV6 exon 6 was found in one case (Dubus et al., 2001). In most leukemia cases, ETV6 exon 5 was fused to NTRK3 exon 15 (Forghieri et al., 2011; Roberts et al., 2014). In one case ETV6 exon 4 was fused to NTRK3 exon 15 (Eguchi: et al., 1999), and in another case, fusion transcripts contain ETV6 exons 1 through 5 fused to NTRK3 exons 13b and 14b or NTRK3 exons 13 through 18 (Kralik et al., 2011).
Fusion Protein
Description	The SAM-PNT (sterile alpha motif- pointed) domain of ETV6 is fused to the PTK (Protein Tyrosine Kinase domain) of NTRK3.
Oncogenesis	It leads to dimerization, and induction of CCND1 (cyclin D1) and increased cell cycle progression. ETV6/NTRK3 also leads to constitutive activation of the PI3K/AKT, RAS/RAF/MAPK, and PLCG pathways (Lannon and Sorensen, 2005).

To be noted

Therapeutic trials with TRK-(tropomyosin receptor kinase) inhibitors are being developed with some remarkable successes (Lange and Lo, 2018).

Bibliography

ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors

Alassiri AH, Ali RH, Shen Y, Lum A, Strahlendorf C, Deyell R, Rassekh R, Sorensen PH, Laskin J, Marra M, Yip S, Lee CH, Ng TL

Am J Surg Pathol 2016 Aug;40(8):1051-61

PMID 27259007

Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma

Anderson J, Gibson S, Sebire NJ

Histopathology 2006 May;48(6):748-53

PMID 16681692

ETV6 Gene Rearrangements Characterize a Morphologically Distinct Subset of Sinonasal Low-grade Non-intestinal-type Adenocarcinoma: A Novel Translocation-associated Carcinoma Restricted to the Sinonasal Tract

Andreasen S, Skálová A, Agaimy A, Bishop JA, Laco J, Leivo I, Franchi A, Larsen SR, Erentaite D, Ulhøi BP, von Buchwald C, Melchior LC, Michal M, Kiss K

Am J Surg Pathol 2017 Nov;41(11):1552-1560

PMID 28719468

Reduced sensitivity of paraffin-based RT-PCR assays for ETV6-NTRK3 fusion transcripts in morphologically defined infantile fibrosarcoma

Argani P, Fritsch MK, Shuster AE, Perlman EJ, Coffin CM

Am J Surg Pathol 2001 Nov;25(11):1461-4

PMID 11684968

Cellular mesoblastic nephroma (infantile renal fibrosarcoma): institutional review of the clinical, diagnostic imaging, and pathologic features of a distinctive neoplasm of infancy

Bayindir P, Guillerman RP, Hicks MJ, Chintagumpala MM

Pediatr Radiol 2009 Oct;39(10):1066-74

PMID 19629465

Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors

Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH

Am J Surg Pathol 2000 Jul;24(7):937-46

PMID 10895816

Integrated genomic characterization of papillary thyroid carcinoma

Cancer Genome Atlas Research Network

Cell 2014 Oct 23;159(3):676-90

PMID 25417114

Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands

Chiosea SI, Griffith C, Assaad A, Seethala RR

Histopathology 2012 Sep;61(3):387-94

PMID 22372712

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy

Church AJ, Calicchio ML, Nardi V, Skalova A, Pinto A, Dillon DA, Gomez-Fernandez CR, Manoj N, Haimes JD, Stahl JA, Dela Cruz FS, Tannenbaum-Dvir S, Glade-Bender JL, Kung AL, DuBois SG, Kozakewich HP, Janeway KA, Perez-Atayde AR, Harris MH

Mod Pathol 2018 Mar;31(3):463-473

PMID 29099503

Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity

Connor A, Perez-Ordoñez B, Shago M, Skálová A, Weinreb I

Am J Surg Pathol 2012 Jan;36(1):27-34

PMID 21989350

Secretory carcinoma of the breast: a genetically defined carcinoma entity

Diallo R, Tognon C, Knezevich SR, Sorensen P, Poremba C

Verh Dtsch Ges Pathol 2003;87:193-203

PMID 16888913

The detection of Tel-TrkC chimeric transcripts is more specific than TrkC immunoreactivity for the diagnosis of congenital fibrosarcoma

Dubus P, Coindre JM, Groppi A, Jouan H, Ferrer J, Cohen C, Rivel J, Copin MC, Leroy JP, de Muret A, Merlio JP

J Pathol 2001 Jan;193(1):88-94

PMID 11169520

Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)

Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, Kudoh S, Tanaka K, Setoyama M, Nagamura F, Asano S, Kamada N

Blood 1999 Feb 15;93(4):1355-63

PMID 9949179

Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement

El Demellawy D, Cundiff CA, Nasr A, Ozolek JA, Elawabdeh N, Caltharp SA, Masoudian P, Sullivan KJ, de Nanassy J, Shehata BM

Pathology 2016 Jan;48(1):47-50

PMID 27020209

Congenital infantile fibrosarcoma

Farmakis SG, Herman TE, Siegel MJ

J Perinatol 2014 Apr;34(4):329-30

PMID 24675019

Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma

Forghieri F, Morselli M, Potenza L, Maccaferri M, Pedrazzi L, Paolini A, Bonacorsi G, Artusi T, Giacobbi F, Corradini G, Barozzi P, Zucchini P, Marasca R, Narni F, Crescenzi B, Mecucci C, Falini B, Torelli G, Luppi M

Eur J Haematol 2011 Apr;86(4):352-5

PMID 21226763

Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature

Ghilli M, Mariniello MD, Scatena C, Dosa L, Traficante G, Tamburini A, Caporalini C, Buccoliero AM, Facchini F, Colizzi L, Quattrini Li A, Landucci E, Manca G, Naccarato AG, Caramella D, Favre C, Roncella M

Breast Cancer Res Treat 2018 Aug;170(3):445-454

PMID 29616377

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG

Nat Commun 2016 Nov 8;7:13331

PMID 27824051

Cellular mesoblastic nephroma: morphologic, cytogenetic and molecular links with congenital fibrosarcoma

Henno S, Loeuillet L, Henry C, D'Hervé D, Azzis O, Ferrer J, Poulain P, Babut JM, Merlio JP, Jouan H, Dubus P

Pathol Res Pract 2003;199(1):35-40

PMID 12650516

Infantile fibrosarcoma of thigh--a case report

Himori K, Hatori M, Watanabe M, Moriya T, Ogose A, Hashimoto H, Kokubun S

Ups J Med Sci 2005;110(1):85-93

PMID 15801689

Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential

Hoda RS, Brogi E, Pareja F, Nanjangud G, Murray MP, Weigelt B, Reis-Filho JS, Wen HY

Histopathology 2019 Aug;75(2):213-224

PMID 31012486

TumorFusions: an integrative resource for cancer-associated transcript fusions

Hu X, Wang Q, Tang M, Barthel F, Amin S, Yoshihara K, Lang FM, Martinez-Ledesma E, Lee SH, Zheng S, Verhaak RGW

Nucleic Acids Res 2018 Jan 4;46(D1):D1144-D1149

PMID 29099951

"Secretory" Carcinoma of the Skin Mimicking Secretory Carcinoma of the Breast: Case Report and Literature Review

Huang S, Liu Y, Su J, Liu J, Guo X, Mei F, Zheng J, Liao S

Am J Dermatopathol 2016 Sep;38(9):698-703

PMID 26981741

Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion

Ito Y, Ishibashi K, Masaki A, Fujii K, Fujiyoshi Y, Hattori H, Kawakita D, Matsumoto M, Miyabe S, Shimozato K, Nagao T, Inagaki H

Am J Surg Pathol 2015 May;39(5):602-10

PMID 25651470

ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma

Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH

Cancer Res 1998 Nov 15;58(22):5046-8

PMID 9823307

Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia

Kralik JM, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H, Wiesinger K, Erdel M, Petzer AL, Webersinke G

Diagn Pathol 2011 Mar 15;6:19

PMID 21401966

Inhibiting TRK Proteins in Clinical Cancer Therapy

Lange AM, Lo HW

Cancers (Basel) 2018 Apr 4;10(4)

PMID 29617282

ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages

Lannon CL, Sorensen PH

Semin Cancer Biol 2005 Jun;15(3):215-23

PMID 15826836

ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer

Leeman-Neill RJ, Kelly LM, Liu P, Brenner AV, Little MP, Bogdanova TI, Evdokimova VN, Hatch M, Zurnadzy LY, Nikiforova MN, Yue NJ, Zhang M, Mabuchi K, Tronko MD, Nikiforov YE

Cancer 2014 Mar 15;120(6):799-807

PMID 24327398

Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy

McCahon E, Sorensen PH, Davis JH, Rogers PC, Schultz KR

Med Pediatr Oncol 2003 May;40(5):288-92

PMID 12652616

Regression of congenital fibrosarcoma to hemangiomatous remnant with histological and genetic findings

Miura K, Han G, Sano M, Tsutsui Y

Pathol Int 2002 Sep;52(9):612-8

PMID 12406191

Differential diagnosis of congenital fibrosarcoma

Morerio C, Rapella A, Rosanda C, Tassano E, Conte M, Gambini C, Panarello C

Cancer Genet Cytogenet 2004 Jul 15;152(2):167-8

PMID 15262440

Congenital fibrosarcoma with metastasis in a fetus

Nonaka D, Sun CC

Pediatr Dev Pathol 2004 Mar-Apr;7(2):187-91

PMID 15022058

Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ): Health Professional Version

PDQ Pediatric Treatment Editorial Board

2020 Jan 9 PDQ Cancer Information Summaries [Internet]

PMID 26389282

Searching for mammary analogue [corrected] secretory carcinoma of salivary gland among its mimics

Pinto A, Nosé V, Rojas C, Fan YS, Gomez-Fernandez C

Mod Pathol 2014 Jan;27(1):30-7

PMID 23807775

ETV6-NTRK3 gene fusion in metastasizing congenital fibrosarcoma

Punnett HH, Tomczak EZ, Pawel BR, de Chadarevian JP, Sorensen PH

Med Pediatr Oncol 2000 Aug;35(2):137-9

PMID 10918240

Cytogenetic and molecular characterization of a congenital mesoblastic nephroma

Ramachandran C, Melnick SJ, Escalon E, Khatib Z, Jhabvala P, Fonseca HB, Smith S, Alamo A, Medina S

Pediatr Dev Pathol 2001 Jul-Aug;4(4):402-11

Retroperitoneal infantile fibrosarcoma: clinical, molecular, and therapeutic aspects of an unusual tumor

Ramphal R, Manson D, Viero S, Zielenska M, Gerstle T, Pappo A

Pediatr Hematol Oncol 2003 Dec;20(8):635-42

PMID 14578034

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group

Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, Chen IM, Valentine M, Liu Y, Li Y, Shao Y, Easton J, Payne-Turner D, Gu Z, Tran TH, Nguyen JV, Devidas M, Dai Y, Heerema NA, Carroll AJ 3rd, Raetz EA, Borowitz MJ, Wood BL, Angiolillo AL, Burke MJ, Salzer WL, Zweidler-McKay PA, Rabin KR, Carroll WL, Zhang J, Loh ML, Mullighan CG, Willman CL, Gastier-Foster JM, Hunger SP

Blood 2017 Jun 22;129(25):3352-3361

PMID 28408464

Congenital fibrosarcoma of the ileum: case report with molecular confirmation and literature review

Rizkalla H, Wildgrove H, Quinn F, Capra M, O'Sullivan MJ

Fetal Pediatr Pathol 2011;30(3):156-60

PMID 21355680

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG

N Engl J Med 2014 Sep 11;371(11):1005-15

PMID 25207766

Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma

Rubin BP, Chen CJ, Morgan TW, Xiao S, Grier HE, Kozakewich HP, Perez-Atayde AR, Fletcher JA

Am J Pathol 1998 Nov;153(5):1451-8

PMID 9811336

Recurrent R-spondin fusions in colon cancer

Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de Sauvage FJ

Nature 2012 Aug 30;488(7413):660-4

PMID 22895193

Congenital-infantile fibrosarcoma

Sheng WQ, Hisaoka M, Okamoto S, Tanaka A, Meis-Kindblom JM, Kindblom LG, Ishida T, Nojima T, Hashimoto H

A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues Am J Clin Pathol

PMID 11242790

Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion

Skálová A, Vanecek T, Simpson RH, Laco J, Majewska H, Baneckova M, Steiner P, Michal M

Am J Surg Pathol 2016 Jan;40(1):3-13

PMID 26492182

Newly described salivary gland tumors

Skalova A, Michal M, Simpson RH

Mod Pathol 2017 Jan;30(s1):S27-S43

PMID 28060365

The landscape of kinase fusions in cancer

Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C

Nat Commun 2014 Sep 10;5:4846

PMID 25204415

Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report

Takahashi A, Kurosawa M, Uemura M, Kitazawa J, Hayashi Y

J Int Med Res 2018 Aug;46(8):3498-3503

PMID 29900760

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma

Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH

Cancer Cell 2002 Nov;2(5):367-76

PMID 12450792

Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression

Vasudev P, Onuma K

Arch Pathol Lab Med 2011 Dec;135(12):1606-10

PMID 22129193

Cryptic t(12;15)(p13;q26) producing the ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in congenital mesoblastic nephroma with trisomy 11: fluorescence in situ hybridization and IGF2 allelic expression analysis

Watanabe N, Kobayashi H, Hirama T, Kikuta A, Koizumi S, Tsuru T, Kaneko Y

Cancer Genet Cytogenet 2002 Jul 1;136(1):10-6

PMID 12165445

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib

Wong V, Pavlick D, Brennan T, Yelensky R, Crawford J, Ross JS, Miller VA, Malicki D, Stephens PJ, Ali SM, Ahn H

J Natl Cancer Inst 2015 Nov 12;108(1)

PMID 26563356

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma

Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, Zhu X, Qu C, Chen X, Zhang J, Easton J, Edmonson M, Ma X, Lu C, Nagahawatte P, Hedlund E, Rusch M, Pounds S, Lin T, Onar-Thomas A, Huether R, Kriwacki R, Parker M, Gupta P, Becksfort J, Wei L, Mulder HL, Boggs K, Vadodaria B, Yergeau D, Russell JC, Ochoa K, Fulton RS, Fulton LL, Jones C, Boop FA, Broniscer A, Wetmore C, Gajjar A, Ding L, Mardis ER, Wilson RK, Taylor MR, Downing JR, Ellison DW, Zhang J, Baker SJ

Nat Genet 2014 May;46(5):444-450

PMID 24705251

ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours

Yamamoto H, Yoshida A, Taguchi K, Kohashi K, Hatanaka Y, Yamashita A, Mori D, Oda Y

Histopathology 2016 Jul;69(1):72-83

PMID 26647767

NTRK3 kinase fusions in Spitz tumours

Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, Vemula SS, Garrido MC, Nakamaru K, Isoyama T, McCalmont TH, LeBoit PE, Bastian BC

J Pathol 2016 Nov;240(3):282-290

PMID 27477320

Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project

Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, Nagahawatte P, Rusch M, Boggs K, Cheng J, Becksfort J, Ma J, Song G, Li Y, Wei L, Wang J, Shurtleff S, Easton J, Zhao D, Fulton RS, Fulton LL, Dooling DJ, Vadodaria B, Mulder HL, Tang C, Ochoa K, Mullighan CG, Gajjar A, Kriwacki R, Sheer D, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Baker SJ, Ellison DW; St

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas Nat Genet

PMID 23583981

Citation

This paper should be referenced as such :

Jean-Loup Huret

t(12;15)(p13;q25) ETV6/NTRK3 in solid tumors

Atlas Genet Cytogenet Oncol Haematol. 2020;24(9):350-356.

Free journal version : [ pdf ]   [ DOI ]

On line version : http://AtlasGeneticsOncology.org/Tumors/t1215p13q25ID5267.html

Translocations implicated (Data extracted from papers in the Atlas)

	t(12;15)(p13;q25) ETV6/NTRK3

External links

Mitelman database	t(12;15)(p13;q25) [CaseList]     t(12;15)(p13;q25) [Transloc - MCList]   ETV6/NTRK3 Fusion - MCList]
COSMIC	[ ETV6 ]   [ NTRK3 ]
arrayMap	Topo ( C18,C19) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
Disease database	t(12;15)(p13;q25) ETV6/NTRK3 in solid tumors

REVIEW articles	automatic search in PubMed
Last year articles	automatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Mon Sep 21 11:23:33 CEST 2020

For comments and suggestions or contributions, please contact us